← BRISTOL MYERS SQUIBB CO (CELG-RI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BRISTOL MYERS SQUIBB CO (CELG-RI)
Pharmaceutical Preparations · market cap $245M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BMS-986249 | Phase 2 | Advanced Cancer |
| Nevirapine | Phase 2 | HIV Infections |
| Vinorelbine (Navelbine) | Phase 2 | Non-small Cell Lung Cancer |
| ISA 101 | Phase 2 | Solid Tumors |
| BMS-754807 | Phase 2 | Breast Cancer |
| Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia |
| Atazanavir/Ritonavir | Phase 3 | HIV |
| Embolization Therapy | Phase 2 | Metastatic Malignant Neoplasm in the Liver |
| Gemcitabine | Phase 2 | Bladder Cancer |
| Chemotherapy (Cisplatin) | Phase 2 | Non Small Cell Lung Cancer |
| pioglitazone hydrochloride | Phase 3 | Type 2 Diabetes |
| Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis |
| CXL-1020 | Phase 2 | Heart Failure |
| Stavudine | Phase 3 | HIV Infections |
| KAI-9803 | Phase 2 | Myocardial Infarction |
| nab-Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer |
| Ixabepilone (Ixempra) | Phase 3 | Breast Cancer |
| BMS-986528 | Phase 2 | Arthritis, Rheumatoid |
| Irinotecan + Carboplatin | Phase 2 | Metastatic Breast Cancer |
| Platinum Doublet | Phase 2 | Resectable Stage IIA to IIIB Non-small Cell Lung Cancer |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$0.10–$0.12
vs 50-day MA
—
vs 200-day MA
—
Realized vol
105.6%
Max drawdown
-16.7%
Daily closes through 2026-09-23. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CELG-RI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.